Alpha 2.0
Login Register
» Authors » Protul Shrikant

Protul Shrikant

Explore the profile of Protul Shrikant including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 1413
Followers 0
Related Specialties
Allergy & Immunology
Oncology
Science
Top 10 Co-Authors
Kunle Odunsi
Shashikant Lele
Junko Matsuzaki
Lloyd J Old
Sacha Gnjatic
Cheryl Eppolito
Amy Beck
Feng Qian
Paulette Mhawech-Fauceglia
Takemasa Tsuji
Published In
J Immunol
Proc Natl Acad Sci U S A
Oncotarget
Immunol Res
J Immunother Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
CXCR6 by increasing retention of memory CD8 T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer
Muthuswamy R, McGray A, Battaglia S, He W, Miliotto A, Eppolito C, et al.
J Immunother Cancer . 2021 Oct; 9(10). PMID: 34607898
Purpose: Resident memory CD8 T cells, owing to their ability to reside and persist in peripheral tissues, impart adaptive sentinel activity and amplify local immune response, and have beneficial implications...
2.
Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses
Matsuzaki J, Tsuji T, Luescher I, Shiku H, Mineno J, Okamoto S, et al.
Sci Rep . 2015 Oct; 5:14896. PMID: 26447332
Tumor antigen-specific CD4(+) T cells generally orchestrate and regulate immune cells to provide immune surveillance against malignancy. However, activation of antigen-specific CD4(+) T cells is restricted at local tumor sites...
3.
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
Huang R, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K
Oncotarget . 2015 Aug; 6(29):27359-77. PMID: 26318293
The immune co-inhibitory receptors lymphocyte activation gene-3 (LAG3) and programmed cell death 1 (PD1) synergistically contribute to autoimmunity and tumor evasion. Here we demonstrate how they collaborate and interact to...
4.
Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells
Matsuzaki J, Tsuji T, Luescher I, Old L, Shrikant P, Gnjatic S, et al.
Cancer Immunol Res . 2014 Apr; 2(4):341-50. PMID: 24764581
Tumor antigen-specific CD4(+) T cells that directly recognize cancer cells are important for orchestrating antitumor immune responses at the local tumor sites. However, the mechanisms of direct MHC class II...
5.
Prostate derived Ets transcription factor and Carcinoembryonic antigen related cell adhesion molecule 6 constitute a highly active oncogenic axis in breast cancer
Mukhopadhyay A, Khoury T, Stein L, Shrikant P, Sood A
Oncotarget . 2013 Apr; 4(4):610-21. PMID: 23592399
We previously reported overexpression of Prostate derived Ets transcription factor (PDEF) in breast cancer and its role in breast cancer progression, supporting PDEF as an attractive target in this cancer....
6.
Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation
Qian F, Liao J, Villella J, Edwards R, Kalinski P, Lele S, et al.
Cancer Immunol Immunother . 2012 Apr; 61(11):2013-20. PMID: 22527253
IDO2 is a newly discovered enzyme with 43 % similarity to classical IDO (IDO1) protein and shares the same critical catalytic residues. IDO1 catalyzes the initial and rate-limiting step in...
7.
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al.
Proc Natl Acad Sci U S A . 2012 Mar; 109(15):5797-802. PMID: 22454499
Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated in clinical trials as cancer vaccines to induce tumor-specific immune responses that will improve clinical outcome. To test...
8.
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models
Shen L, Ciesielski M, Ramakrishnan S, Miles K, Ellis L, Sotomayor P, et al.
PLoS One . 2012 Feb; 7(1):e30815. PMID: 22303460
Background: Immunosuppressive factors such as regulatory T cells (Tregs) limit the efficacy of immunotherapies. Histone deacetylase (HDAC) inhibitors have been reported to have antitumor activity in different malignancies and immunomodulatory...
9.
Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype
Yeh N, Glosson N, Wang N, Guindon L, McKinley C, Hamada H, et al.
J Immunol . 2010 Jul; 185(4):2089-98. PMID: 20624947
CD8 T cells can acquire cytokine-secreting phenotypes paralleling cytokine production from Th cells. IL-17-secreting CD8 T cells, termed Tc17 cells, were shown to promote inflammation and mediate immunity to influenza....
10.
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al.
Proc Natl Acad Sci U S A . 2010 Apr; 107(17):7875-80. PMID: 20385810
NY-ESO-1 is a "cancer-testis" antigen frequently expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic tumor antigens defined to date. In an effort to understand in vivo...